SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2019

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.

Cuc Thi Thu Nguyen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.